The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of MRD and post-remission strategies on outcomes following dose-dense mini-hyper-CVD inotuzumab and blinatumomab in relapsed B-cell acute lymphoblastic leukemia.
 
Maria Hachem
No Relationships to Disclose
 
Hannah Goulart
No Relationships to Disclose
 
Nitin Jain
Honoraria - Abbvie/Genentech; Adaptive Biotechnologies; Adaptive Biotechnologies; ADC Therapeutics; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pfizer; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Celgene (Inst); Cellectis (Inst); CRC Oncology (Inst); Dialectic Therapeutics (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); KisoJi Biotechnology (Inst); Kite, a Gilead company (Inst); Loxo/Lilly (Inst); Medisix Therapeutics (Inst); Medisix Therapeutics (Inst); MingSight (Inst); Newave Pharmaceutical (Inst); NovalGen (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Precision Biosciences (Inst); Sana Biotechnology (Inst); SERVIER (Inst); Takeda (Inst); TransThera Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - CRLF2 Bispecific antibody
 
Lewis Nasr
No Relationships to Disclose
 
Farhad Ravandi-Kashani
Honoraria - Agios; Astellas Pharma; Celgene
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb Foundation; Celgene; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - MacroGenics
 
Tapan Kadia
Honoraria - CURE
Consulting or Advisory Role - Abbvie/Genentech; Agios; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/UCB Japan; Jazz Pharmaceuticals; Liberum; Novartis; Pfizer; Pinot Bio; Sanofi; Sellas Life Sciences; SERVIER; SOBI; Syndax
Research Funding - Abcuro; Amgen; Ascentage Pharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Celgene; cellenkos; Cyclacel; DAAN Biotherapeutics; Delta-Fly Pharma; Genentech/Abbvie; Genfleet Therapeutics; Glycomimetics; Incyte; Iterion Therapeutics; Jazz Pharmaceuticals; Pfizer; Pulmotech; Regeneron (Inst); Sellas Life Sciences
 
Courtney DiNardo
Honoraria - Abbvie; Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Genentech/Abbvie; GlaxoSmithKline; Schrodinger; SERVIER
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Molecular Partners; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER
Research Funding - Abbvie; Astex Pharmaceuticals; BeiGene; Bristol-Myers Squibb/Celgene; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Jazz Pharmaceuticals; Loxo/Lilly; Remix Therapeutics; SERVIER
 
Naval Daver
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; SERVIER; Shattuck Labs; Stemline/Menarini; Syndax; Trillium Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); FATE Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immunogen (Inst); Kite, a Gilead company (Inst); Novimmune (Inst); Pfizer (Inst); Servier (Inst); Trillium Therapeutics (Inst); Trovagene (Inst)
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Consulting or Advisory Role - Abbvie; BMS Consulting; CTI; GSK Consulting; Immunogen; Incyte; JNJ; Karyopharm Therapeutics; Menarini-Stemline Group; MorphoSys; OPNA; Pacylex; Protagonist Therapeutics; SOBI; Takeda
Research Funding - US DOD (Inst)
Other Relationship - Karger Publishers
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Fadi Haddad
Honoraria - GlaxoSmithKline; Novartis
Consulting or Advisory Role - Cardinal Health; Takeda
 
Alex Bataller
No Relationships to Disclose
 
Rita Khouri
No Relationships to Disclose
 
Jayastu Senapati
(OPTIONAL) Uncompensated Relationships - Omeros Pharma
 
Christina Simon
No Relationships to Disclose
 
Rebecca Garris
No Relationships to Disclose
 
Guillermo Garcia-Manero
Honoraria - Ascentage Pharma; Bristol-Myers Squibb/Celgene; Curis; Keros Therapeutics
Consulting or Advisory Role - Ascentage Pharma; Bristol-Myers Squibb; Curis; Keros Therapeutics; SERVIER; Taiho Oncology; Takeda
Research Funding - Abbvie; Ascentage Pharma; AstraZeneca; Bristol-Myers Squibb; Chordia Therapeutics; Curis; Genentech; GlaxoSmithKline; Novartis; Rigel; SERVIER; Taiho Oncology; Takeda; Zentalis
 
Nicholas Short
Honoraria - Adaptive Biotechniologies; Amgen; Astellas Pharma; AstraZeneca; Merck; Novartis; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Autolus; GlaxoSmithKline; Merck; Novartis; Pfizer; Sanofi; Syndax; Takeda
Research Funding - Ascentage Pharma; Astellas Pharma; GlaxoSmithKline; HemOgenyx; NextCure; Novartis; Takeda; Vironexis; Xencor
 
Hagop Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; KAHR Medical; Novartis; Pfizer; Shenzhen Target Rx
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Elias Jabbour
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma; Autolus; Bristol-Myers Squibb; Genentech; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; TargetRX; Terns Pharmaceuticals
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Terns Pharmaceuticals; TGRX
Travel, Accommodations, Expenses - Aptitude Health; Autolus; Daiichi Sankyo Nordics; HMP Education; MD Education; Nucleus Global; ONVIV; Pfizer